Cerus Corporation (CERS) Shares Sold by TIAA CREF Investment Management LLC
TIAA CREF Investment Management LLC lowered its position in Cerus Corporation (NASDAQ:CERS) by 19.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 313,561 shares of the biotechnology company’s stock after selling 74,935 shares during the quarter. TIAA CREF Investment Management LLC owned approximately 0.30% of Cerus Corporation worth $787,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in CERS. Russell Investments Group Ltd. bought a new position in Cerus Corporation in the first quarter worth approximately $137,000. Bank of New York Mellon Corp grew its stake in Cerus Corporation by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 505,652 shares of the biotechnology company’s stock worth $2,250,000 after purchasing an additional 6,710 shares in the last quarter. American International Group Inc. grew its stake in Cerus Corporation by 7.1% in the first quarter. American International Group Inc. now owns 62,374 shares of the biotechnology company’s stock worth $278,000 after purchasing an additional 4,127 shares in the last quarter. Vanguard Group Inc. grew its stake in Cerus Corporation by 7.9% in the first quarter. Vanguard Group Inc. now owns 4,708,427 shares of the biotechnology company’s stock worth $20,952,000 after purchasing an additional 343,597 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Cerus Corporation by 3.7% in the first quarter. Geode Capital Management LLC now owns 823,882 shares of the biotechnology company’s stock worth $3,666,000 after purchasing an additional 29,731 shares in the last quarter. 55.62% of the stock is currently owned by institutional investors.
Shares of Cerus Corporation (CERS) opened at $3.58 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.71 and a debt-to-equity ratio of 0.80. Cerus Corporation has a twelve month low of $1.93 and a twelve month high of $5.91.
Cerus Corporation (NASDAQ:CERS) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The company had revenue of $10.80 million during the quarter, compared to analyst estimates of $11.95 million. Cerus Corporation had a negative return on equity of 142.18% and a negative net margin of 159.35%. Cerus Corporation’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.14) earnings per share. equities analysts anticipate that Cerus Corporation will post -0.59 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/11/14/cerus-corporation-cers-shares-sold-by-tiaa-cref-investment-management-llc.html.
Several research analysts recently issued reports on CERS shares. Cowen and Company set a $6.00 price objective on Cerus Corporation and gave the stock a “buy” rating in a research note on Thursday, October 5th. Zacks Investment Research raised Cerus Corporation from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Wednesday, November 8th. BidaskClub raised Cerus Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, ValuEngine cut Cerus Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $6.40.
Cerus Corporation Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Stock Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related stocks with our FREE daily email newsletter.